Rare diseases
Investigational molecules
Locations
345 conditions with trials, the busiest first
956 trials across Europe, recruiting first
Study of Azenosertib (ZN-c3) for Women with Recurrent or Persistent Uterine Serous Carcinoma
FranceStudy of Imlunestrant, Fulvestrant, Exemestane, and Abemaciclib for Patients with Advanced Estrogen Receptor Positive, HER2 Negative Breast Cancer
AustriaStudy comparing giredestrant plus palbociclib versus letrozole plus palbociclib in patients with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer
AustriaStudy of Niraparib, Abiraterone Acetate, and Prednisone for Patients with Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer
BelgiumStudy of Niraparib, Abiraterone Acetate, and Prednisone for Patients with Metastatic Prostate Cancer
BelgiumStudy of palbociclib with hormone therapy versus hormone therapy alone in patients with recurrent hormone receptor-positive/HER2-negative breast cancer after surgery
AustriaStudy of Pembrolizumab, Vibostolimab, and Belzutifan for Patients with Metastatic Castration-Resistant Prostate Cancer
AustriaStudy of Stereotactic Body Radiotherapy with or without Darolutamide for Patients with Oligorecurrent Prostate Cancer
BelgiumStudy of Niraparib and Dostarlimab Combined with Platinum Therapy for Newly Diagnosed Stage III or IV Non-mucinous Epithelial Ovarian Cancer
BelgiumStudy of Nadunolimab with Gemcitabine and Carboplatin for Patients with Advanced Triple Negative Breast Cancer
SpainStudy on Metformin to Prevent High Blood Sugar in Advanced Breast Cancer Patients with Alpelisib and Endocrine Therapy
SpainStudy of Farletuzumab Ecteribulin vs. Chemotherapy for Women with Platinum-resistant High-grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
BelgiumThe therapies tested most often in Reproductive system and breast disorders trials.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
